Biocure Technology Inc. (BICTF)
USD 0.0
(-95.51%)
USD 0.0
(-95.51%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 373.24 Thousand CAD | -91.54% |
| 2022 | 4.41 Million USD | 11.48% |
| 2021 | 3.95 Million CAD | -26.56% |
| 2020 | 5.38 Million CAD | 39.96% |
| 2019 | 3.84 Million CAD | 41.38% |
| 2018 | 2.72 Million CAD | 172.86% |
| 2017 | 997.97 Thousand CAD | -24.68% |
| 2016 | 1.32 Million CAD | -50.47% |
| 2015 | 2.67 Million CAD | 1909.43% |
| 2014 | 133.12 Thousand CAD | 166.4% |
| 2013 | 49.97 Thousand CAD | -71.9% |
| 2012 | 177.84 Thousand CAD | 208.53% |
| 2011 | 57.64 Thousand CAD | -57.87% |
| 2010 | 136.81 Thousand CAD | 171.24% |
| 2009 | 50.44 Thousand CAD | 537.86% |
| 2008 | 7908.00 CAD | 31.8% |
| 2007 | 6000.00 CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 294.7 Thousand USD | 4.65% |
| 2024 Q2 | 321.49 Thousand USD | 49.3% |
| 2023 Q2 | 672.83 Thousand USD | -78.78% |
| 2023 Q1 | 3.17 Million USD | -2.55% |
| 2023 Q4 | 281.61 Thousand USD | -57.95% |
| 2023 Q3 | 669.73 Thousand USD | -0.46% |
| 2023 FY | 373.24 Thousand CAD | -91.54% |
| 2022 Q4 | 3.25 Million USD | 25.58% |
| 2022 FY | 4.41 Million USD | 11.48% |
| 2022 Q1 | 2.74 Million CAD | -30.69% |
| 2022 Q2 | 2.65 Million CAD | -3.26% |
| 2022 Q3 | 2.59 Million CAD | -2.34% |
| 2021 Q4 | 3.95 Million CAD | -36.87% |
| 2021 Q2 | 6.82 Million CAD | 5.28% |
| 2021 FY | 3.95 Million CAD | -26.56% |
| 2021 Q1 | 6.47 Million CAD | -5.61% |
| 2021 Q3 | 6.26 Million CAD | -8.1% |
| 2020 Q1 | 5.06 Million CAD | 1.47% |
| 2020 FY | 5.38 Million CAD | 39.96% |
| 2020 Q2 | 5.43 Million CAD | 7.38% |
| 2020 Q4 | 6.86 Million CAD | 17.48% |
| 2020 Q3 | 5.84 Million CAD | 7.42% |
| 2019 Q1 | 2.2 Million CAD | -18.99% |
| 2019 Q2 | 3.03 Million CAD | 37.77% |
| 2019 Q4 | 4.99 Million CAD | 63.43% |
| 2019 Q3 | 3.05 Million CAD | 0.51% |
| 2019 FY | 3.84 Million CAD | 41.38% |
| 2018 Q2 | 1.5 Million CAD | 51.94% |
| 2018 Q4 | 2.72 Million CAD | 61.88% |
| 2018 FY | 2.72 Million CAD | 172.86% |
| 2018 Q1 | 992 Thousand CAD | -0.6% |
| 2018 Q3 | 1.68 Million CAD | 11.6% |
| 2017 Q3 | 143.43 Thousand CAD | 27.48% |
| 2017 FY | 997.97 Thousand CAD | -24.68% |
| 2017 Q1 | - CAD | -100.0% |
| 2017 Q2 | 112.51 Thousand CAD | 0.0% |
| 2017 Q4 | 997.97 Thousand CAD | 595.76% |
| 2016 FY | 1.32 Million CAD | -50.47% |
| 2016 Q4 | 1.32 Million CAD | 440.79% |
| 2016 Q3 | 245.01 Thousand CAD | 17.4% |
| 2016 Q2 | 208.7 Thousand CAD | 9.68% |
| 2016 Q1 | 190.28 Thousand CAD | -4.4% |
| 2015 FY | 2.67 Million CAD | 1909.43% |
| 2015 Q3 | 164.05 Thousand CAD | 10.1% |
| 2015 Q4 | 199.04 Thousand CAD | 21.33% |
| 2015 Q1 | 133.12 Thousand CAD | 20.19% |
| 2015 Q2 | 149 Thousand CAD | 11.93% |
| 2014 Q2 | 73.61 Thousand CAD | 47.31% |
| 2014 Q1 | 49.97 Thousand CAD | 92.87% |
| 2014 Q3 | 94.99 Thousand CAD | 29.05% |
| 2014 Q4 | 110.77 Thousand CAD | 16.6% |
| 2014 FY | 133.12 Thousand CAD | 166.4% |
| 2013 Q3 | 207.95 Thousand CAD | 7.54% |
| 2013 Q4 | 25.91 Thousand CAD | -87.54% |
| 2013 FY | 49.97 Thousand CAD | -71.9% |
| 2013 Q1 | 177.84 Thousand CAD | 23.5% |
| 2013 Q2 | 193.36 Thousand CAD | 8.72% |
| 2012 FY | 177.84 Thousand CAD | 208.53% |
| 2012 Q2 | 304.03 Thousand CAD | 427.43% |
| 2012 Q4 | 144 Thousand CAD | 7.83% |
| 2012 Q3 | 133.55 Thousand CAD | -56.07% |
| 2012 Q1 | 57.64 Thousand CAD | 22.89% |
| 2011 Q3 | 33.91 Thousand CAD | -40.39% |
| 2011 Q1 | 136.81 Thousand CAD | -26.85% |
| 2011 Q2 | 56.88 Thousand CAD | -58.42% |
| 2011 FY | 57.64 Thousand CAD | -57.87% |
| 2011 Q4 | 46.9 Thousand CAD | 38.32% |
| 2010 Q2 | 149.87 Thousand CAD | 44.06% |
| 2010 FY | 136.81 Thousand CAD | 171.24% |
| 2010 Q4 | 187.04 Thousand CAD | 27.95% |
| 2010 Q1 | 104.03 Thousand CAD | 92.54% |
| 2010 Q3 | 146.18 Thousand CAD | -2.46% |
| 2009 Q4 | 54.03 Thousand CAD | 7.12% |
| 2009 FY | 50.44 Thousand CAD | 537.86% |
| 2009 Q2 | 1800.00 CAD | 0.0% |
| 2009 Q1 | - CAD | -100.0% |
| 2009 Q3 | 50.44 Thousand CAD | 2702.33% |
| 2008 Q2 | 270.00 CAD | -99.02% |
| 2008 Q1 | 27.47 Thousand CAD | 153.89% |
| 2008 Q3 | 7908.00 CAD | 2828.89% |
| 2008 Q4 | 7500.00 CAD | -5.16% |
| 2008 FY | 7908.00 CAD | 31.8% |
| 2007 Q4 | 10.82 Thousand CAD | 0.0% |
| 2007 FY | 6000.00 CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Qrons Inc. | 1.48 Million USD | 74.928% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 99.368% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 53.852% |
| Adynxx, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -85.586% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 99.257% |
| BioStem Technologies, Inc. | 15.9 Million USD | 97.653% |
| CSL Limited | 18.62 Billion USD | 99.998% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 96.057% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 99.485% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 99.502% |
| Regen BioPharma, Inc. | 5.45 Million USD | 93.161% |
| Skye Bioscience, Inc. | 14.07 Million USD | 97.348% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -735.07% |
| Rebus Holdings, Inc. | 5.24 Million USD | 92.88% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -1260.562% |
| Neon Bloom, Inc. | 1.22 Million USD | 69.561% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 99.3% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 96.105% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | 11.463% |
| SQZ Biotechnologies Company | 50.03 Million USD | 99.254% |
| Intellipharmaceutics International Inc. | 12 Million USD | 96.892% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 90.309% |
| Mesoblast Limited | 188.44 Million USD | 99.802% |
| Marizyme, Inc. | 26.67 Million USD | 98.601% |
| Genus plc | 485 Million USD | 99.923% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 93.612% |
| Pharming Group N.V. | 244.07 Million USD | 99.847% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 81.432% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 85.167% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 90.178% |
| ContraFect Corporation | 32.53 Million USD | 98.853% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 81.162% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 90.249% |
| IMV Inc. | 37.93 Million USD | 99.016% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 96.831% |
| MultiCell Technologies, Inc. | 1617.67 USD | -22972.876% |
| ONE Bio Corp. | 27.49 Million USD | 98.643% |
| Accustem Sciences Inc. | 1.07 Million USD | 65.416% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 99.518% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 82.353% |
| Q BioMed Inc. | 8.13 Million USD | 95.411% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 99.55% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 92.747% |
| Biomind Labs Inc. | 1.49 Million USD | 75.094% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 99.686% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 95.872% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 97.972% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 73.969% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -162.671% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 93.504% |
| GB Sciences, Inc. | 5.41 Million USD | 93.11% |
| Alpha Cognition Inc. | 7.16 Million USD | 94.791% |
| HST Global, Inc. | 593.59 Thousand USD | 37.121% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 70.359% |
| Halberd Corporation | 728.71 Thousand USD | 48.781% |
| Enzolytics Inc. | 365.26 Million USD | 99.898% |
| Agentix Corp. | 2.51 Million USD | 85.133% |
| Resverlogix Corp. | 67.39 Million USD | 99.446% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 55.499% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.916% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 78.224% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 98.492% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 96.864% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 89.816% |
| AVAX Technologies, Inc. | 3.99 Million USD | 90.654% |
| Zenith Capital Corp. | 27.56 Thousand USD | -1253.85% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.972% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -56.395% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 90.005% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | 45.179% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 86.236% |
| Kadimastem Ltd | 3.5 Million USD | 89.351% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -457.67% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | 19.681% |
| LadRx Corporation | 2.2 Million USD | 83.038% |
| Cell Source, Inc. | 15.8 Million USD | 97.639% |
| Regen BioPharma, Inc. | 5.45 Million USD | 93.161% |
| NovAccess Global Inc. | 7.86 Million USD | 95.252% |
| Affymax, Inc. | 8.87 Million USD | 95.793% |
| Itoco Inc. | 1.65 Million USD | 77.422% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 81.807% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 93.83% |
| Mobile Lads Corp. | 1.31 Million USD | 71.584% |
| CytoDyn Inc. | 127.89 Million USD | 99.708% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -792.947% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 76.172% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 96.621% |
| SYBLEU INC | 681.41 Thousand USD | 45.225% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 93.883% |
| International Stem Cell Corporation | 5.27 Million USD | 92.927% |
| Bioxytran, Inc. | 3.24 Million USD | 88.514% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | 40.358% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 91.916% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 99.09% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 98.324% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 81.572% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 93.187% |
| Neutra Corp. | 973.52 Thousand USD | 61.661% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 98.714% |
| PureTech Health plc | 125.58 Million USD | 99.703% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 90.066% |
| IXICO plc | 1.9 Million USD | 80.359% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 98.182% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.639% |
| CSL Limited | 18.62 Billion USD | 99.998% |
| Cellectis S.A. | 249.36 Million USD | 99.85% |